Clinical Trials Directory

Trials / Unknown

UnknownNCT05773209

Choroidal and Retinal Changes After RLRL Therapy in Diabetes and Diabetic Retinopathy

Effect of Repeated Low-level Red-light (RLRL) Therapy on the Choroid and the Retina in Diabetes and Diabetic Retinopathy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
58 (estimated)
Sponsor
The Second People's Hospital of Foshan · Academic / Other
Sex
All
Age
35 Years – 55 Years
Healthy volunteers
Not accepted

Summary

The choroidal thickness was found to be thinner in diabetic eyes without retinopathy compared to healthy eyes, thus choroidal thickness might be an important parameter for the development of diabetic retinopathy in diabetic eyes without retinopathy. Repeated low-level red-light (RLRL) therapy is an emerging innovative and non-invasive treatment for a variety of eye diseases. Notably, RLRL was found to be effective in thickening choroidal thickness in a 1-year randomized controlled trial, indicating its potential in modulating blood flow in the fundus. This study aims to answer whether RLRL therapy can thicken choroidal thickness in adults with diabetes mellitus or diabetic retinopathy.

Detailed description

The goal of this study is to investigate the effect of repeated low-level red-light (RLRL) therapy on the choroidal and retinal structures in diabetes mellitus and diabetic retinopathy. This study will be conducted with a prospective randomized cross-over design with a total follow-up of 3 months. The control group will use the sham device but with only 5% of the original device's power. Comprehensive ophthalmic examinations, including visual acuity, intraocular pressure, optical coherence tomography, optical coherence tomography angiography, slit lamp will be assesses at baseline and within the follow up

Conditions

Interventions

TypeNameDescription
DEVICERLRL deviceCrossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.

Timeline

Start date
2023-04-30
Primary completion
2023-10-30
Completion
2023-12-30
First posted
2023-03-17
Last updated
2023-04-18

Source: ClinicalTrials.gov record NCT05773209. Inclusion in this directory is not an endorsement.